HIPEC With Cisplatin, Mitomycin, and Paclitaxel for Gastric Adenocarcinoma and Associated Carcinomatosis or Positive Cytology

Gastric cancer patients whose disease had spread to the peritoneum received infusions of mitomycin, cisplatin and paclitaxel into the peritoneum in a clinical trial and had 1- and 2-year survival rates of 74% and 58%.